CommercialCoverageLow impact
Zevaskyn (prademagene zamikeracel)
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Wound Care, Pediatrics·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 20, 2026
Summary
BCBSMS has added a new policy (L.5.01.628) designating Zevaskyn (prademagene zamikeracel), a gene therapy for rare skin condition RDEB, as not medically necessary. A new HCPCS code J3389 was added effective 01/01/2026 and will be denied unless prior authorization is obtained through BCBSMS PA review process.
Action Required
By January 1, 2026: Billing team must update system to flag HCPCS code J3389 (prademagene zamikeracel) as requiring prior authorization through BCBSMS PA review process before billing. Code will be considered not medically necessary without prior approval. Update billing software to prevent claim submission without PA number.